BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Lowers Stock Holdings in Trillium Therapeutics Inc. (NASDAQ:TRIL)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lowered its holdings in shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) by 5.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 444,555 shares of the biotechnology company’s stock after selling 26,348 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned approximately 0.42% of Trillium Therapeutics worth $4,306,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Bourgeon Capital Management LLC boosted its position in Trillium Therapeutics by 30.1% during the first quarter. Bourgeon Capital Management LLC now owns 30,250 shares of the biotechnology company’s stock worth $325,000 after purchasing an additional 7,000 shares in the last quarter. Toronto Dominion Bank boosted its position in Trillium Therapeutics by 45.4% during the first quarter. Toronto Dominion Bank now owns 10,143 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 3,165 shares in the last quarter. Nicholas Investment Partners LP boosted its position in Trillium Therapeutics by 75.5% during the first quarter. Nicholas Investment Partners LP now owns 1,346,753 shares of the biotechnology company’s stock worth $14,464,000 after purchasing an additional 579,369 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in Trillium Therapeutics by 53.5% during the first quarter. Cubist Systematic Strategies LLC now owns 11,972 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 4,172 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Trillium Therapeutics during the first quarter worth approximately $239,000. Institutional investors own 80.86% of the company’s stock.

Shares of Trillium Therapeutics stock opened at $17.36 on Wednesday. Trillium Therapeutics Inc. has a one year low of $5.80 and a one year high of $20.96. The company has a market cap of $1.82 billion, a price-to-earnings ratio of 28.00 and a beta of 2.21. The business’s 50 day moving average price is $10.53 and its 200 day moving average price is $10.02.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last announced its quarterly earnings data on Thursday, August 12th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.04). Equities analysts predict that Trillium Therapeutics Inc. will post -0.87 EPS for the current fiscal year.

Several research firms have recently weighed in on TRIL. HC Wainwright downgraded Trillium Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from C$22.00 to C$18.50 in a research report on Monday, August 23rd. JMP Securities downgraded Trillium Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, August 24th. Craig Hallum downgraded Trillium Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the company from $21.00 to $18.50 in a research report on Tuesday, August 24th. Finally, Zacks Investment Research downgraded Trillium Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 19th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $20.33.

In related news, insider Robert Uger sold 3,646 shares of Trillium Therapeutics stock in a transaction that occurred on Wednesday, July 7th. The stock was sold at an average price of $9.00, for a total transaction of $32,814.00. Following the transaction, the insider now owns 3,646 shares in the company, valued at $32,814. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 9.10% of the company’s stock.

Trillium Therapeutics Company Profile

Trillium Therapeutics, Inc is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Read More: How to Trade Using Analysts Ratings

Institutional Ownership by Quarter for Trillium Therapeutics (NASDAQ:TRIL)

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.